$108 Million is the total value of CAXTON CORP's 26 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 44.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SBBP | Buy | STRONGBRIDGE BIOPHARMA PLC | $32,928,000 | +11.3% | 6,612,065 | +0.1% | 30.56% | -14.9% |
| KALA | Buy | KALA PHARMACEUTICALS INC | $12,416,000 | +87.0% | 1,501,272 | +10.6% | 11.52% | +43.0% |
| MEIP | MEI PHARMA INC | $10,620,000 | +16.3% | 3,459,124 | 0.0% | 9.86% | -11.0% | |
| MTEM | MOLECULAR TEMPLATES INC | $9,437,000 | +43.8% | 1,624,241 | 0.0% | 8.76% | +10.0% | |
| Buy | GARRISON CAP INC | $8,796,000 | +12.3% | 1,225,096 | +0.6% | 8.16% | -14.1% | |
| SCYX | SCYNEXIS INC | $6,531,000 | +213.5% | 4,325,000 | 0.0% | 6.06% | +139.8% | |
| CMFN | Sell | CM FIN INC | $6,322,000 | -1.6% | 856,673 | -16.7% | 5.87% | -24.8% |
| ABDC | Buy | ALCENTRA CAP CORP | $6,000,000 | +1132.0% | 800,000 | +962.4% | 5.57% | +842.1% |
| AMLP | Buy | ALPS ETF TRalerian mlp | $4,131,000 | +14.9% | 411,892 | +0.0% | 3.83% | -12.1% |
| SPY | SPDR S&P 500 ETF TRtr unit | $3,958,000 | +13.1% | 14,010 | 0.0% | 3.67% | -13.5% | |
| BRKB | BERKSHIRE HATHAWAY INC DELcl b new | $1,871,000 | -1.6% | 9,312 | 0.0% | 1.74% | -24.7% | |
| ARQL | Buy | ARQULE INC | $700,000 | +102.9% | 146,066 | +17.4% | 0.65% | +55.1% |
| EIGR | Buy | EIGER BIOPHARMACEUTICALS INC | $689,000 | +55.2% | 49,285 | +12.8% | 0.64% | +18.6% |
| SNSS | New | SUNESIS PHARMACEUTICALS INC | $337,000 | – | 277,245 | +100.0% | 0.31% | – |
| KURA | Sell | KURA ONCOLOGY INC | $320,000 | -30.6% | 19,274 | -41.3% | 0.30% | -46.9% |
| CTIC | Buy | CTI BIOPHARMA CORP | $313,000 | +244.0% | 323,026 | +160.6% | 0.29% | +163.6% |
| GSM | New | FERROGLOBE PLC | $285,000 | – | 139,226 | +100.0% | 0.26% | – |
| MRKR | Sell | MARKER THERAPEUTICS INC | $280,000 | -5.4% | 42,374 | -20.5% | 0.26% | -27.6% |
| FPAC | Sell | FAR PT ACQUISITION CORP | $253,000 | -3.4% | 25,453 | -6.1% | 0.24% | -26.1% |
| SBPH | Buy | SPRING BK PHARMACEUTICALS IN | $249,000 | +13.7% | 23,717 | +12.8% | 0.23% | -13.2% |
| FSK | Sell | FS KKR CAPITAL CORP | $245,000 | -41.8% | 40,458 | -50.3% | 0.23% | -55.6% |
| DRNA | Buy | DICERNA PHARMACEUTICALS INC | $230,000 | +54.4% | 15,727 | +12.8% | 0.21% | +17.7% |
| MELI | New | MERCADOLIBRE INC | $221,000 | – | 435 | +100.0% | 0.20% | – |
| AMT | New | AMERICAN TOWER CORP NEW | $216,000 | – | 1,097 | +100.0% | 0.20% | – |
| CACC | New | CREDIT ACCEP CORP MICH | $208,000 | – | 460 | +100.0% | 0.19% | – |
| TDG | New | TRANSDIGM GROUP INC | $208,000 | – | 458 | +100.0% | 0.19% | – |
| MRNS | Exit | MARINUS PHARMACEUTICALS INC | $0 | – | -61,443 | -100.0% | -0.21% | – |
| ARCC | Exit | ARES CAP CORP | $0 | – | -17,553 | -100.0% | -0.33% | – |
| Exit | INTEC PHARMA LTD JERUSALEM | $0 | – | -42,236 | -100.0% | -0.39% | – | |
| ACRS | Exit | ACLARIS THERAPEUTICS INC | $0 | – | -61,264 | -100.0% | -0.55% | – |
| JBGS | Exit | JBG SMITH PPTYS | $0 | – | -22,349 | -100.0% | -0.94% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MOLECULAR TEMPLATES INC | 24 | Q2 2023 | 30.7% |
| STRONGBRIDGE BIOPHARMA PLC | 22 | Q3 2021 | 73.1% |
| GARRISON CAP INC | 18 | Q3 2020 | 9.9% |
| BERKSHIRE HATHAWAY INC DEL | 17 | Q3 2019 | 5.8% |
| EIGER BIOPHARMACEUTICALS INC | 17 | Q3 2022 | 1.7% |
| AGILE THERAPEUTICS INC | 16 | Q1 2018 | 55.5% |
| KALA PHARNACEUTICALS INC | 16 | Q4 2021 | 17.6% |
| CM FIN INC | 16 | Q1 2019 | 7.8% |
| SYNTA PHARMACEUTICALS CORP | 15 | Q2 2016 | 99.9% |
| CTI BIOPHARMA CORP | 14 | Q4 2021 | 8.7% |
View CAXTON CORP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Addex Therapeutics Ltd. | February 14, 2023 | 718,849 | 0.9% |
| Cardiff Oncology, Inc. | February 14, 2023 | 983,607 | 2.2% |
| Rezolute, Inc. | February 14, 2023 | 1,860,518 | 5.0% |
| Xeris Biopharma Holdings, Inc. | February 14, 2023 | 5,973,324 | 4.4% |
| CTI BIOPHARMA CORP | February 14, 2022 | 2,239,300 | 2.3% |
| Sierra Oncology, Inc. | February 14, 2022 | 1,119,322 | 7.0% |
| Strongbridge Biopharma plcSold out | January 05, 2022 | 0 | 0.0% |
| SUNESIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
| Alcentra Capital Corp | February 14, 2020 | 1,005,000 | 7.8% |
| Garrison Capital Inc. | February 14, 2020 | 1,223,096 | 7.6% |
View CAXTON CORP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View CAXTON CORP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.